Pfizer: Hemophilia A trials

The registry lists 47 Hemophilia A studies with Pfizer as lead sponsor. 6 are open to participants now and 27 have results posted.

Phase 1 5Phase 2 4Phase 3 15Phase 4 9No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without InhibitorsRecruitingNCT07923981Phase 3
• A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or BNot yet recruitingNCT07859527
• A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.RecruitingNCT06703606Phase 1
• A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Phase 3
• Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B RespectivelyRecruitingNCT05568719Phase 3
• Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Phase 3
• Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe HemophiliaCompletedNCT04878731Phase 1Results posted
• Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A PatientsCompletedNCT04396639Phase 4Results posted
• Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A AdultsActive, not recruitingNCT04370054Phase 3Results posted
• Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BCompletedNCT03938792Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia BActive, not recruitingNCT03861273Phase 3Results posted
• A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)CompletedNCT03587116Phase 3Results posted
• PF-06741086 Long-term Treatment in Severe HemophiliaCompletedNCT03363321Phase 2Results posted
• Understanding Hemophilia A and B Drug Dosage Administration PatternsTerminatedNCT03248141Results posted
• A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia ACompletedNCT03061201Phase 2Results posted
• Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled SyringeCompletedNCT03034044Results posted
• PF-06741086 Multiple Dose Study in Severe HemophiliaCompletedNCT02974855Phase 2Results posted
• Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort StudyCompletedNCT02740413Results posted
• PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia ACompletedNCT02492984Phase 4Results posted
• Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia ACompletedNCT02461992Phase 1Results posted
• Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGOCompletedNCT01959919Results posted
• Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia ACompletedNCT01790828Results posted
• Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care SettingCompletedNCT00950170Phase 4Results posted
• Study Evaluating Liver Transplantation in Haemophilia Patients in SpainCompletedNCT00927992Results posted
• Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A PatientsCompletedNCT00914459Phase 4Results posted
• Study Evaluating Pharmacovigilance Of Refacto AFCompletedNCT00895037Results posted
• Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care SettingsTerminatedNCT00884390Phase 4Results posted
• Study Evaluating On-Demand Treatment Of Xyntha In Chinese SubjectsCompletedNCT00868530Phase 3Results posted
• Study Evaluating The Safety Of Xyntha In Usual Care SettingsTerminatedNCT00765726Phase 4Results posted
• Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of AgeTerminatedNCT00759655Phase 3Results posted
• Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIIICompletedNCT00543439Phase 3Results posted
• Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major SurgeryCompletedNCT00243659Phase 3Results posted
• Study Evaluating Refacto For PharmacovigilanceCompletedNCT00195442Results posted
• A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.Active, not recruitingNCT07161687
• Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & BWithdrawnNCT06634836
• A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) DeviceTerminatedNCT04832139Phase 1
• Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia BTerminatedNCT03307980Phase 2
• Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine ProphylaxisWithdrawnNCT02718677
• Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)CompletedNCT01579903Phase 1
• Study Evaluating Approach to Treatment of Haemophilia A and B in SpainCompletedNCT00581438
• Study Comparing Blood Levels of ReFacto and Advante in Hemophilia AWithdrawnNCT00168051Phase 4
• Study Evaluating Inhibitor Specificity in Hemophilia AWithdrawnNCT00151385Phase 4
• Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia ACompletedNCT00141843Phase 3
• Study Evaluating ReFacto® in Hemophilia A Undergoing Major SurgeryCompletedNCT00092976Phase 4
• Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia ACompletedNCT00038935Phase 3
• Study Evaluating ReFacto in Hemophilia ACompletedNCT00038909Not applicable
• Study Evaluating ReFacto AF in Severe Hemophilia ACompletedNCT00037544Phase 3